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ABSTRACT 
Role of Phe95 In the Receptor Binding of 
Influenza B Virus Hemagglutinin 
by 
Fengyun Ni 
Influenza A and B viruses are significant human pathogens responsible for the annual 
seasonal "flu". Diverged some 2000 years ago, influenza B virus has several 
important differences from influenza A virus, including lower receptor-binding 
affmity and very limited host range. Based on sequence comparison and our prior 
structural studies, we hypothesized that a key difference in the receptor-binding site of 
influenza virus hemagglutinin (HA), phenylalaline (Phe) 95 in influenza B virus HA 
(BHA), versus tyrosine (Tyr) in influenza A virus HA (AHA), is possibly the 
molecular basis for the different receptor-binding affinity. We further hypothesized 
that this could be at least partially responsible for the very limited host range of 
influenza B virus. By using glycan and red blood cell binding assays, we 
demonstrated that the mutation Phe95~ Tyr in BHA substantially enhanced 
receptor-binding affinity. Furthermore, this mutation efficiently competed against the 
infection of influenza A virus and greatly improved the binding of BHA to three 
mammalian cell lines. Taken together, residue 95 of BHA appears to be a key 
determinant for the receptor binding affinity and host range of influenza B virus. 
III 
Abbreviations: 
HA: Hemagglutinin; BHA: Influenza B virus Hemagglutinin; SA: Sialic Acid; RBC: 
Red Blood Cell; MDCK: Madin Darby Canine Kidney. 
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1. Introduction 
Great efforts have been dedicated to the understandings of the replication of 
influenza viruses, where each step of the virus infection might be a potential target for 
prophylactic and therapeutic treatment. The discemable phases of influenza virus 
replication can be briefly described as: 1) Virus attachment and entry to the host cell; 
2) Virion assembly; and 3) Release from the host cell (1). Profound progresses were 
made during the recent years from different scientific research fields. Structural 
characterizations of several important proteins of influenza viruses provide the 
templates for drug designs, including the envelop glycoproteins hemagglutinin (HA) 
and neuraminidase (NA), M2 ion-channel protein, the subunits {PA, PB 1 and PB2) of 
viral polymerase complex and nonstructural (NS) protein (see reference 2 for some of 
the solved structures). 
One of the unsolved issues is that the underlying mechanism that accounts for the 
different host ranges for influenza A and B viruses, which are two main types of 
influenza virus responsible for the seasonal "flu" epidemics each year. Based on the 
sequence comparison and our recent X-ray structure of the influenza B virus 
hemagglutinin (BHA}, which mediates the attachment of the virus to the receptors on 
the host cell, show that its receptor binding site has a phenylalaline (Phe) at position 
95, versus tyrosine {Tyr) in influenza A virus HA (3). We hypothesize that this key 
difference is possibly the molecular basis for the different receptor-binding affinity 
and this could be at least partially responsible for the very limited host range of 
influenza B virus. 
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In order to test this hypothesis, we make the mutation Phe95~ Tyr on BHA for 
biochemical and biological studies. Although naturally occurring influenza B viruses 
frequently have asparagine (Asn) and serine (Ser) at HAl 194 and 196 respectively, 
making a glycosylation site at Asnl94, there are cases where this glycosylation site 
was abolished in, for example, some field isolates ( 4, 5), and egg-adapted variants 
(6-12), as a result of mutations at HAl 194 and 196. Thus, to comprehensively study 
the effects of residue at position 95, Phe versus Tyr, we constructed the mutation 
Phe95~Tyr on both background sequences, with a glycosylation site at Asnl94 
(wild type), or without a glycosylation site (Asp 194, Asn 194~Asp ). 
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2. Methods and materials 
2.1. Cloning, expression and purification of BHA and its mutants 
The DNA of hemagglutinin of influenza BNM/73 (BHA) virus was obtained by 
RT-PCR. The BHA fragment was cloned to pRB21 plasmid to facilitate the expression 
in vaccinia systems. The site-directed mutagenesis was used to make the Phe95~ Tyr, 
Asn194~Asp and Phe95~Tyr/Asn194~Asp mutants of BHA. All constructs 
contained anN-terminal signal peptide, a C-terminal "foldon" sequence and a His-tag 
at the extreme C-terminus. The recombinant vaccinia viruses were generated in CV-1 
cells and the all the constructs mainly expressed the unprocessed HAO. The CV-1 cells 
were maintained in DMEM medium supplemented with 10% FBS. For a typical 
preparation, 400 mL confluent CV-1 monolayer cells were infected at multiplicity of 
infection (MOl) of 1. After three days, the supernatant was collected and dialyzed. 
The soluble BHA was recovered from the supernatant by HisPur Cobalt Resin 
(Thermo Fisher Scientific Inc.) The beads bound with BHA were treated with 
neuraminidase (Sigma) to prevent the sialic acid-mediated aggregation in the 
following concentrating steps. The BHA was eluted with 500 mM Imidazole and was 
exchanged to buffer of 20 mM Tris-HCl (pH 7.2), 50 mM NaCl, then subjected to 
anion-exchange (mono-Q 4.6/100 PE, GE Healthcare) and gel-filtration 
chromatography (Superdex 200 10/300 GL, GE Healthcare ). Only the peak according 
to the BRA-trimer was collected for the glycan assays and red blood cell binding 
assays. The protein concentration was qualified by Bradford protein assay. For the 
Asn194~Asp and Phe95~Tyr/Asn194~Asp mutants, the glycosylation site was 
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depleted in order to mimic the situation that the influenza B vtrus lost its 
glycosylation site at this position after egg adaptation. Correspondingly, the molecular 
weights of the HAO monomer for these two mutants were about 3 kD smaller than 
that of wild type BHA as shown on the SDS-PAGE (data not shown). 
2.2. Dose-dependent glycan assay 
To characterize the receptor binding properties of BHA and its mutants, biotinylated 
a(2,3) (3 ' SLN, 3'SLN-LN and 3'SLN-LN-LN) and a(2,6) (6 ' SLN and 6' SLN-LN) 
glycans from the Consortium of Functional Glycomics (www.functionalglycomics.org) 
were used in the dose-dependent glycan assay. LN represents lactosamine 
(GalP1-4GlcNAc), 3'SLN and 6'SLN represent Neu5Aca2-3 and Neu5Aca2-6 
linked to LN, respectively. The different glycans were first diluted to 2.4 J..lM and 
loaded to the streptavidin-coated high binding capacity 384-well plates (Pierce), 
followed by incubating at 4 degree overnight. The excessive glycans were removed 
by washing with PBS for three times. The pre-complex of BHA, mouse anti-His 
antibody (0.2 mg/ml, Sigma) and anti-mouse-IgG antibody (2 mg/ml, Sigma) was 
prepared in a molar ratio of 4:2:1. The mixture was incubated on ice for 20 minutes, 
and the pre-complex was diluted to the expected concentration with 1% BSA in PBS. 
Each glycan-coated well was then loaded with 50 J..ll of the pre-complex of BHA and 
incubated at room temperature for 2 hours followed by wash with 0.05% Tween-20 in 
PBS to remove the unbound pre-complex. The Amplex Red Peroxidase Assay 
(Invitrogen) was used to measure the binding signal based on the HRP activity. 
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Negative controls, where no pre-complexes were loaded in those wells, were included 
for each glycan and the assays were performed in triplicate. To quantify the binding 
affinity, the assays were also performed at lower concentration range (0.05 to 1 f.lg/ml) 
for 3'SLN-LN and 6'SLN-LN. The Hill equation was used to represent the binding of 
the pre-complex of BHA to the coated glycan. 
2.3. Red blood cell binding assay 
Thirty micro-liter Ni-NTA resin (Thermo Fisher Scientific Inc.) was loaded with 2.5 
f.lg BHA and incubated at room temperature for 2 hours. The beads were centrifuged 
down and the unbound BHA in supernatant was removed. The beads were then 
blocked with 3% BSA in PBS for 30 minutes. The supernatant was removed after 
spinning down the beads and the beads were washed with PBS extensively. The red 
blood cells (RBCs) were washed with Alsever's solution until the supernatant turns to 
be clear. The RBCs were stored as 50% in Alsever's solution after the final wash. The 
RBCs were then added to the BHA-coated beads in the final concentration of 0.5% 
and incubated at room temperature for 30 minutes. Finally, the beads were washed 
gently with PBS for appropriate imaging under microscope. 
2.4. Influenza A virus infection inhibition assay in MDCK cells 
For this assay, the BHA eluted from the Cobalt resin was used. The purity of BHA 
was about 85% to 90% as determined by the SDS-PAGE. The MDCK cells were 
seeded at appropriate concentration in 96-well plate one day before to achieve the 
6 
100% confluency when the assays were performed. The cell monolayer was washed 
with DPBS twice and complete DMEM (0.2% BSA, 25 mM HEPES in DMEM) once. 
The expected amount of BHA was loaded into different wells and complete DMEM 
was added to make all the wells contain same volume of supernatant. After the plate 
was incubated at room temperature for 1 hour, 5 HAU per 50 J..ll 1% human RBC of 
influenza A/Brisbane virus and TPCK-trypsin (final concentration was 2 J..tg/ml, 
Worthington) were added to wells and the plate was incubated at 37 degree for 1 hour 
(5% C02). The supernatant was removed and the wells were washed twice with 
complete DMEM. Finally, each well was loaded with 100 J..ll influenza virus growth 
medium (complete DMEM with 2 J..tg/ml TPCK-trypsin). After 24 hours of infection, 
the supernatant was centrifuged (300 g, 15 minute) to pellet the cellular debris and 
used for the standard hemagglutination assay with 1% human RBC. All the assays 
were performed in triplicate. 
2.5. Cell-based ELISA assay 
In order to quantitatively detect the binding of receptors on the cell surface to BHA, 
cell-based Elisa assay was carried out with three cell lines including MDCK, BHK21 
and Vero. For this assay, the BHA eluted from the Cobalt resin was used. The 
confluent cell monolayer in white 96-well plate (FALCON) was first washed with 
DPBS and expected amount of BHA diluted with 1% BSA in DPBS was added to 
different wells, complete DMEM was added to make all the wells have the same 
volume of solution. The plate was incubated at room temperature for 1 hour. The 
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supernatant was removed and each well was washed with DPBS for three times 
followed by being added 100 J!l 3.7% formaldehyde diluted in DPBS for 10 minutes. 
The fixative was removed, and wells were washed with PBST (0.1% Triton X-100 in 
PBS) for three times. The wells were then blocked with 10% FBS for 1 hour at room 
temperature followed by incubation with primary antibody (mouse anti-His antibody, 
Sigma, 1 :4000 dilution with 1% BSA in PBST) for 1 hour at room temperature. The 
wells were then washed three times with PBST. The wells were finally incubated with 
secondary antibody (HRP-conjugated anti-mouse-IgG, Sigma, dilution 1 :40000) for 1 
hour at room temperature. After washing with PBST and PBS, the binding signal was 
measured with ECL reagent (Amersham). All the assays were performed in triplicate. 
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3. Results 
3.1. Results of glycan assay 
Using recombinant BHA expressed in mammalian cells by vaccinia virus system 
(13), we first performed dose-dependent glycan binding assay using three 
a(2,3)-linked avian-like receptors and two a(2,6)-linked human-like receptors. It was 
apparent that the wild-type BHA preferentially binds to the long a(2,6)-linked 
human-like receptor (6'SLN-LN) (Fig. 1a). The mutation Phe95~Tyr simultaneously 
enhanced the binding for both avian-like (3'SLN-LN-LN) and human-like 
(6'SLN-LN) receptors in the long format (Fig.lb). The calculated apparent binding 
constants for the wild-type and Phe95~Tyr BHA were 13.4 mM and 2.44 J..LM for the 
3'SLN-LN receptor, and 0.13 mM and 10.5 pM for the 6'SLN-LN receptor, 
respectively (Table 1). Not surprisingly, the mutation Asn194~Asp, which causes the 
loss of a glycosylation site at HA 1 194-196, as frequently found in egg-adapted 
variants (6-12), results in the preferential binding to a(2,3)-linked avian-like receptors, 
with an apparent binding constant of 2.9 pM for 3'SLN-LN, in contrast to the 0.209 
mM binding constant for a(2,6)-linked 6'SLN-LN (Fig.1c, Table 1). As seen for the 
single Phe95~Tyr mutant, the double mutant Phe95~Tyr/Asn194~Asp improves the 
binding for both a(2,3)-linked and a(2,6)-linked receptors (Fig.1d), with apparent 
binding constants of 0.45 pM and 1.90 pM for 3'SLN-LN and 6'SLN-LN, 
respectively (Table 1 ). Thus, regardless of whether or not there is a glycosylation at 
HA 1 194-196, the mutation Phe95~ Tyr enhances the binding of BHA for both avian 
and human-like receptors in an indiscriminative manner. 
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Fig.l. The mutation Phe95~Tyr promotes the binding of BHA to synthetic glycans in 
dose-dependent glycan assay (A-D) and glycan microarray analysis (E-H). The five glycans 
used in the dose-dependent assay are 3'SLN (• ), 3'SLN-LN (• ), 3'SLN-LN-LN ( ), 6' SLN ( ) 
and 6'SLN-LN (• ). See Materials and Methods for the full name of each glycan. The binding 
signals (A-D) are expressed as the percentage of the maximum fluorescence intensity. Wild type 
BHA shows significant binding only to long a(2,6) (6 ' SLN-LN), while its Phe95-7Tyr mutant 
binds to long a(2,3) (3'SLN-LN-LN) and long a(2,6) (6 'SLN-LN) almost identically (Compare B 
with A). With the loss of glycosylation site at 194, the Asn194-7 Asp mutant shows higher binding 
to long a(2,3) (3'SLN-LN and 3'SLN-LN-LN) (Compare C with A), while the binding capacity to 
long a(2,6) (6'SLN-LN) of the Phe95-7Tyr/Asn194-7Asp mutant increases (CompareD with C). 
Only those glycans with absolute fluorescence intensities above 5000 are shown for the glycan 
microarray assay (E-H). The glycans are categorized into a(2,3)-linked sialosides (• ), 
a(2,6)-linked sialosides (• ), free sialic acid (•) and others (• ). The full names of these glycans are 
listed in Table S 1. Wild type BHA binds to limited number of glycans, while its Phe95-7Tyr 
mutant can bind to a few more a(2,3) and a(2,6) (Compare F with E). The loss of glycosylation 
site at 194 causes the Asn194-7 Asp mutant to bind more a(2,3) but less a(2,6) (Compare G with 
E). The Phe95-7Tyr/Asn194-7Asp mutant binds to the most number of a(2,3) and a(2,6) (H). 
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To analyze further the glycan binding properties of Phe95~ Tyr mutants, we 
performed glycan microarray assay using 465 different glycans. Shown in Fig.le~h 
are the binding profiles for 94 glycans that yielded significant binding signals in the 
glycan microarray assay. All these 94 glycans had terminal sialic acid groups. 
Consistent with the results of dose-dependent glycan binding assays, the wild-type 
BHA preferentially binds to a(2,6)-linked receptors (Fig.le, red colors), while 
Asn194~Asp preferentially binds to a(2,3)-linked receptors (Fig. lg, green colors). 
The mutants Phe95~Tyr and Phe95~Tyr/Asn194~Asp have much stronger binding 
for both a(2,6)-linked and a(2,3)-linked receptors (Fig.lf, lh). It is worth noting that 
BHA proteins with a glycosylation at HAl 194~196, the wild type and Phe95~Tyr 
mutant, had an overall weaker binding for glycans than their counterparts without a 
glycosylation (Fig.la~h, Table 1), agreeing with an earlier observation. 
Table 1 The relative binding affinities ofBHA to a(2,3) and a(2,6) receptors 
BHA 3'SLN-LN 6'SLN-LN 
n Kd' R2 n Kd' R2 
Wild type 0.426 13.4mM 0.9816 0.604 0.134 mM 0.9714 
Phe957Tyr 0.868 2.44J.l.M 0.9969 1.26 10.5 pM 0.9970 
Asn1947Asp 1.49 2.90pM 0.9982 0.728 0.209 mM 0.9877 
Phe957Tyr/Asn1947Asp 1.45 0.45 pM 0.9800 1.65 1.90 pM 0.9710 
The apparent binding constant Kd', cooperativity factor n and the R-square R2 were obtained by 
fitting the data to the linear Hill equation in order to quantitatively determine the relative binding 
affmities of BHAs, and their absolute values should be compared only in this context. 
One interesting observation from the glycan microarray results was that the 
Phe95~ Tyr mutant displays substantial enhanced binding for two free sialic acids of 
different lengths (shown in black colors in Fig.le~h), suggesting that the gain in 
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binding to receptors by Phe95~ Tyr is probably the result of a much tighter binding 
between the extra hydroxyl group of the introduced Tyr95 with the terminal sialic acid 
on the receptors, which would also help explain its indiscriminative binding for both 
human and avian-like receptors. To explore this explanation further, we made a 
Phe95~ Tyr mutation on our previously published structures of BRA-receptor 
complexes in silico (Fig.2) (14). By using the second most popular side chain 
conformation and a small adjustment in torsion angles, Tyr95 in BHA was easily 
placed at a position similar to Tyr98 in the structure of AHA H3 subtype without any 
potential structural clash (Fig.2). At this position and without any structural 
adjustment of the terminal sialic acid, the newly added hydroxyl group of Tyr95 forms 
two hydrogen bonds with the terminal sialic acid and one additional bond with His 191 
(Fig.2 in red dashed lines). Thus, these extra hydrogen bonds introduced by the Tyr95 
residue are most likely the molecular basis for the improved binding affinity of 
Phe95~ Tyr with receptors. 
B 
-
Fig.2. Sialic acid binding with BHA (A), model structure of Phe95~Tyr mutant (B) and 
AHA (C). In the model structure ofPhe95~Tyr mutant, the hydroxyl group ofTyr95 could form 
two more hydrogen bonds with sialic acid moiety and one more hydrogen bond with His 191 as 
compared with those in wild type BHA crystal structure (A). These three extra hydrogen bonds 
exist in the crystal structure of AHA (C). 
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3.2. Results of red blood cells binding assay 
Red blood cells from different species are known to contain varying amounts of 
avian and/or human-like receptors. Thus, if the enhanced binding affinity of 
Phe95-+ Tyr for synthetic receptors holds true, we would expect that this mutation 
allows better binding for natural sialic acid receptors on many different red blood cell 
types. Toward this end, we tested red blood cells from eight species (Fig.3). All four 
proteins were found to bind well to human red blood cells. Compared with their 
corresponding wild-type proteins, both Phe95-+Tyr and Phe95-+Tyr/Asn194-+Asp 
mutants bound significantly better for red blood cells from chicken, turkey, and 
guinea pig, and somewhat better for those from rabbit and bovine. For the red blood 
cells from swine, the mutant Phe95-+ Tyr bound significantly better while 
Phe95-+Tyr/Asn194-+Asp only bound slightly better than their corresponding 
wild-type proteins (Fig.3). Therefore, the higher binding affinity of the Phe95-+ Tyr 
and Phe95-+Tyr/Asn194-+Asp mutants for synthetic receptors can be readily 
translated into a much stronger binding to natural sialic acid receptors on red blood 
cells. 
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Wild type Pbe95~Tyr Asn194~Asp Pbe9S~Tyr/Asni94~Asp 
Human 
Chicken 
Turkey 
Guinea 
pig 
Swine 
Rabbit 
Bovine 
Sheep 
Fig.3. Red blood cell (RBC) binding assay. The species are listed on the left. Wild type BHA and 
its mutants bind equally well to human RBCs. The Phe95-7Tyr and Phe95-7Tyr/Asn194-7Asp 
mutants show better binding toward chicken, turkey, guinea pig, swine and rabbit RBCs than wild 
type BHA and the Asn194-7Asp mutant, respectively. There are no big binding differences with 
bovine and sheep RBCs for wild type BHA and its mutants. 
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3.3. Results of influenza A virus infection inhibition assay in MDCK cells 
Since binding to cell-surface receptors is a prerequisite for infecting host cells by 
influenza virus, we asked whether the much higher binding affinity of the Phe95~ Tyr 
and Phe95~Tyr/Asn194~Asp mutants would allow them to compete more 
effectively against infection caused by influenza virus. As a most stringent test, we 
used influenza A/H3N2 virus (A/Brisbane/2007) that generally has much higher 
binding affinity for cell-surface receptors than influenza B virus. The test also 
included a "blank" where no influenza A virus was added and a "positive control" 
where only influenza A virus was added (Fig.4). Using five hemagglutination units 
(HAU) of influenza A virus as input to infect Madin Darby Canine Kidney (MDCK) 
cells, at 48 hour post-infection, the "positive control" had a virus titer of about 32 
HAU per 50 f.!L 1% human red blood cells. With 400 f..lg recombinant proteins, the 
Phe95~Tyr mutant displayed four-fold stronger inhibition of influenza A virus than 
its wild type, which had about two-fold inhibition over the "positive control". Most 
strikingly, the mutant Phe95~Tyr/Asn194~Asp completely blocked the infection of 
influenza A virus, with as low as 200 f.!g (Fig.4) and 100 f..lg (data not shown) 
recombinant proteins. In marked contrast, with 200 f.,lg recombinant protein, the 
Asn194~Asp yielded a virus titer of 32 HAU per 50 f.!L 1% human red blood cells 
(Fig.4). Although MDCK cells have both a(2,6)-linked and a(2,3)-linked sialic acid 
receptors, it was speculated that the a(2,3)-linked sialic acid receptors are in a much 
low abundance than a(2,6)-linked sialic acid receptors (15). This may explain the 
roughly two-fold inhibition displayed by the wild-type BHA that preferentially binds 
to a(2,6)-linked sialic acid receptors, in contrast to the null inhibition exhibited by the 
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Asn 194~Asp mutant (Fig.4 ). Therefore, the higher binding affinity of the Phe95~ Tyr 
and Phe95~Tyr/Asnl94~Asp mutants for synthetic and natural sialic acid receptors 
did allow a much stronger competition against influenza virus infection. 
A 
Po itive Wild type Phe95-Tyr A nl94-+Asp Pbe95-+Tyr/ 
Asn 194-+Asp 
Fig.4. The mutation Phe95~ Tyr efficiently inhibits the binding of influenza A virus to 
MDCK cells. The "Blank" sample is the negative control where the MDCK cells grow under 
normal condition in the binding inhibition assay. The "Positive" sample is the positive control 
where the MDCK cells are infected with 5 HAU influenza A virus. The "Wild type" and 
"Phe95-7Tyr" samples represent those wells where the MDCK cells are first binding with 400 J..Lg 
wild type BHA and Phe95-7Tyr mutant before the infection of 5 HAU influenza A virus, 
respectively. The "Asnl94-7Asp" and "Phe95-7Tyr/Asnl94-7Asp" samples are for those wells 
where the MDCK cells are first binding with 200 J..Lg Asnl94-7 Asp and 
Phe95-7Tyr/Asnl94-7Asp mutants before the infection of 5 HAU influenza A virus. The 
supernatants after 24-hour incubation are used for the hemagglutination assay (upper figure). If 
there are enough viruses at certain dilution, the lattice will form due to the interactions 
(agglutination) between RBC and hemagglutinin on the surface of influenza A viruses (shown as 
pink circle); otherwise the RBC will settle to the bottom of the well to form a red button (shown as 
a small red circle in a big pink circle). The titer is read as the endpoint of agglutination (lower 
figure). The titers are much smaller if Phe95 is mutated to Tyr95 as compared Phe95-7Tyr with 
wild type or Phe95-7Tyr/Asnl94-7Asp with Asnl94-7Asp, meaning that the virus could not 
grow well if Phe95-7Tyr or Phe95-7Tyr/Asn194-7Asp is present. This indicates that the 
Phe95-7Tyr and Phe95-7Tyr/Asnl94-7Asp mutants could compete against the hemagglutinins on 
the influenza A virus in the binding to the receptors on the MDCK cells, thus inhibit the entrance 
of influenza A virus. 
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3.4. Results of cell-based ELISA 
Based on the results of influenza virus infection inhibition assay presented above, 
we asked whether there is a correlation between receptor-binding affinity of BHA and 
the host range of influenza B virus. In other words, would the enhanced 
receptor-binding affinity of the Phe95__.Tyr and Phe95__.Tyr/Asn194__.Asp mutants 
allow BHA to bind a number of host cells significantly better? To explore this, we 
developed a whole-cell-based ELISA assay that quantitatively measures the amount of 
BHA proteins immobilized on cell culture monolayers due to their association with 
cell-surface receptors (see Methods for details). Three established cell lines were used: 
MDCK, Baby hamster kidney (BHK21 ), and African green monkey kidney (Vero ). 
Although MDCK is a well-established cell line for influenza A and B viruses, mixed 
successes were obtained for BHK21 and Vero in supporting influenza B virus growth 
(16). The wild-type BHA generally had a very weak binding to all three cell lines, 
with the weakest for BHK21 cell line (Fig.5). The mutation Phe95__.Tyr substantially 
improved the binding to all three cell lines, while the most significant improvement 
was seen for the Vero cell line (Fig.5). The Asn194__.Asp mutant had a similar binding 
affinity as the Phe95__. Tyr on the wild-type background, but the 
Phe95__.Tyr/Asn194__.Asp enhanced the binding affinity by around 1000-fold over 
those of Asn194__.Asp (Fig.5). Taken together, the mutation Phe95__.Tyr allowed for a 
much tighter binding to all the three cell lines tested here, thus satisfying the first 
prerequisite for the ability of influenza B virus to bind and infect a wide range of 
hosts. 
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Fig.S. The mutation Phe95~Tyr enhances the binding ofBHA to the surface of cultured cells. 
The binding signals are expressed as the percentage of the maximum chemiluminescence intensity 
for MDCK (A), BHK21 (B) and Vero (C) in cell-based ELISA. In all three cell lines tested, 
wild-type BHA has the weakest binding, while the Phe95~Tyr/Asn194~Asp mutant shows the 
strongest binding. 
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4. Concluding Discussion 
It is well established that naturally occurring influenza B virus has much lower 
binding affinity for synthetic glycans and natural receptors on cell surface, and it also 
has a very limited host range, infecting mostly humans. It remains an open question 
whether there exists a correlation between the limited host range and the lower 
receptor binding affinity. We use dose-dependent glycan assay and glycan microarray 
assay to show that the mutant Phe95~ Tyr could increase the binding of BHA with 
synthetic glycans, and red blood cell binding assay to show that this mutation 
increases the binding of BHA with natural receptors. The higher binding affinity of 
the Phe95~ Tyr mutant for synthetic and natural sialic acid receptors did allow a much 
stronger competition against influenza virus infection as shown in the influenza A 
virus infection binding assay. Further, the Phe95~ Tyr mutant could bind with 
different host cell lines with high affinities. Together, these results suggest that the 
residue at position 95 should be the key for revealing the mechanism of limited host 
range and pathogenicity of influenza B virus. 
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